G01N 2800/7052
Fibrosis
G01N2800/7052 (Fibrosis) appears on 32 US grants and 94 published applications in this corpus.
Search patents in G01N- Granted patents
- 32
- Published applications
- 94
- Assignees
- 83
- Inventors
- 220
- Latest grant
- 26 May 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2004 | 0 | 1 |
| 2005 | 0 | 0 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 1 |
| 2010 | 0 | 1 |
| 2011 | 0 | 0 |
| 2012 | 0 | 4 |
| 2013 | 1 | 3 |
| 2014 | 1 | 4 |
| 2015 | 0 | 1 |
| 2016 | 0 | 10 |
| 2017 | 4 | 11 |
| 2018 | 2 | 8 |
| 2019 | 5 | 4 |
| 2020 | 3 | 13 |
| 2021 | 1 | 2 |
| 2022 | 4 | 8 |
| 2023 | 2 | 8 |
| 2024 | 5 | 3 |
| 2025 | 3 | 10 |
| 2026 | 1 | 2 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Method for NASH risk assessment26 May 2026US 12,638,460 B2Genfit
- Anti-FAM19A5 antibodies and uses thereof9 Dec 2025US 12,492,246 B2Neuracle Science Co., Ltd.
- Anti C-MET antibodies16 Sep 2025US 12,415,861 B2Centessa Pharmaceuticals (UK) Limited
- CD146 and uses thereof as a biomarker and as a therapeutic target in the diagnosis and treatment of fibrosis9 Sep 2025US 12,411,143 B2Assistance Publique - Hopitaux De Marseille
- Combination of biomarkers for detecting and evaluating a hepatic fibrosis8 Oct 2024US 12,110,551 B2Ariana Pharmaceuticals
- Anti c-met antibodies12 Feb 2026US 2026/0042850 A1Centessa Pharmaceuticals (UK) Limited
- Biomarkers for fibrosis treatment using anti-claudin-1 antibodies8 Jan 2026US 2026/0008845 A1Alentis Therapeutics AG
- Cd146 and uses thereof as a biomarker and as a therapeutic target in the diagnosis and treatment of fibrosis4 Dec 2025US 2025/0369988 A1Assistance Publique - Hopitaux De Marseille
- Anti-fam19a5 antibodies and uses thereof30 Oct 2025US 2025/0333491 A1Neuracle Science Co., Ltd.
- Microfluidic devices for evaluating fibrosis in material implantation and cancer4 Sep 2025US 2025/0277785 A1The United States of America as represented by the Secretary, Department of Health and Human Service
Most cited
By later US patents
- Anti-FAM19A5 antibodies and uses thereof7US 11,618,783 B2Neuracle Science Co., Ltd. · 2023
- Combination of biomarkers for detecting and evaluating a hepatic fibrosis4US 10,435,744 B2Ariana Pharmaceuticals · 2019
- Combination of biomarkers for the detection and evaluation of hepatitis fibrosis4US 9,624,541 B2Ariana Pharmaceuticals · 2017
- Devices and methods related to airway inflammation1US 10,670,594 B2Children's Healthcare of Atlanta, Inc. · 2020
- Fibroblast activation protein (FAP) targeted imaging and therapy in fibrosis1US 11,426,472 B2Purdue Research Foundation · 2022